Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI / NKI-AVL)

Research facility


Location: Amsterdam, Netherlands (NL) NL

ISNI: 0000000106741393

ROR: https://ror.org/03xqtf034

Show on Map:

close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Gene-Environment Interactions Relevant to Estrogen and Risk of Breast Cancer: Can Gene-Environment Interactions Be Detected Only among Candidate SNPs from Genome-Wide Association Studies? (2021) Park J, Choi JY, Choi J, Chung S, Song N, Park SK, Han W, et al. Journal article Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium (2021) Morra A, Jung AY, Behrens S, Keeman R, Ahearn TU, Anton-Culver H, Arndt V, et al. Journal article Exclusive endocrine therapy or partial breast irradiation for women aged ≥70years with luminal A-like early stage breast cancer (NCT04134598 – EUROPA): Proof of concept of a randomized controlled trial comparing health related quality of life by patient reported outcome measures (2021) Meattini I, Poortmans PM, Marrazzo L, Desideri I, Brain E, Hamaker M, Lambertini M, et al. Journal article Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk (2021) Kapoor PM, Mavaddat N, Choudhury PP, Wilcox AN, Lindström S, Behrens S, Michailidou K, et al. Journal article Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women (2021) Dorling L, Carvalho S, Allen J, Gonzalez-Neira A, Luccarini C, Wahlstrom C, Pooley KA, et al. Journal article Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition (2021) Rogiers A, Da Silva IP, Tentori C, Tondini CA, Grimes JM, Trager MH, Nahm S, et al. Journal article Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. (2021) Bottomley A, Coens C, Mierzynska J, Blank CU, Mandalà M, Long GV, Atkinson VG, et al. Journal article Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. (2021) Eggermont AM, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, et al. Journal article Corrigendum to ‘Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival’: [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024] (Annals of Oncology (2021) 32(8) (1015–1024), (S0923753421015532), (10.1016/j.annonc.2021.05.353)) (2021) Slamon DJ, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S, Petrakova K, et al. Journal article, Erratum Risk factors associated with positive surgical margins’ location at radical cystectomy and their impact on bladder cancer survival (2021) Claps F, Van De Kamp MW, Mayr R, Bostrom PJ, Boormans JL, Eckstein M, Mertens LS, et al. Journal article
‹ 1 ... 5 6 7 8 9 ... 18 ›